Atrial fibrillation articles from across Nature Portfolio

A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a better understanding of the mechanisms that link these conditions.

Administrative-driven hierarchical management (ADHM) encourages general practitioners to act as voluntary gatekeepers in China’s non-mandatory medical system. Here the authors show that ADHM lowers cardiovascular events, mortality, and healthcare costs in atrial fibrillation patients compared with usual care.

Corrado et al. use cardiac digital twins from 100 atrial fibrillation patients to evaluate how electrolyte imbalances influence atrial electrophysiology and arrhythmia risk. Hyponatremia is identified as a key determinant of sustained AF, while hypokalemia modestly increases the likelihood of arrhythmia onset.

Oral anticoagulants are the cornerstone of stroke risk prevention in patients with atrial fibrillation, regardless of whether sinus rhythm is restored. Evidence from two new randomized trials questions the need for long-term treatment with oral anticoagulants after successful ablation of atrial fibrillation and promises to change clinical practice.

A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a better understanding of the mechanisms that link these conditions.

Sura Markos discusses the findings from the INVICTUS trial and the implications for anticoagulation strategies in patients with rheumatic atrial fibrillation, particularly in low-resource settings.

In patients with symptomatic paroxysmal atrial fibrillation, pulsed field ablation is non-inferior to cryoballoon ablation for preventing the recurrence of atrial tachyarrhythmia, according to findings from the SINGLE SHOT CHAMPION trial.